Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | Director | June 03, 2026 | June 04, 2026 |
| Vericel CorpVCEL · Entity 4481 | Director · President and CEO | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Trevi Therapeutics, Inc.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.45 · Expires 2036-06-02 | Direct | 35,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 35,000 · Balance 35,000 F1: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.
Vericel Corp
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 303,020 |
Reported balance
After 2026-02-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 303,020 F1: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. F2: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 321,270 |
Reported balance
After 2026-02-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 321,270 F4: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 312,446 |
Reported balance
After 2026-02-24 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-02-24 · Tax withholding · Disposed 8,824 · Balance 312,446 F5: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 36,500 |
Reported balance
After 2026-02-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 36,500 F6: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F2: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. F7: No expiration date for this type of award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 54,750 |
Reported balance
After 2026-02-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-24 · Exercise / conversion · Acquired 18,250 · Balance 54,750 F6: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F8: The Fair Market Value of the vested derivative securities is $38.09 per share. F4: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. F7: No expiration date for this type of award. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.
F2: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F4: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively.
F5: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
F6: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
F7: No expiration date for this type of award.
F8: The Fair Market Value of the vested derivative securities is $38.09 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2018 Filed May 18, 2018 20:00 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 17,812 | $1.95 | $34,733.40 |
DisclosureSEC source: 0001593968-18-000790 · primary_01.xml · nonDerivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:00 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,548 | $3.02 | $4,674.96 |
DisclosureSEC source: 0001593968-18-000790 · primary_01.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:00 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 10,000 | $2.75 | $27,500.00 |
DisclosureSEC source: 0001593968-18-000790 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:00 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 20,000 | $14.01 | $280,200.00 |
DisclosureSEC source: 0001593968-18-000790 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,085 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2018. Read SEC document |
| May 16, 2018 Filed May 18, 2018 20:00 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 900 | $14.00 | $12,600.00 |
DisclosureSEC source: 0001593968-18-000790 · primary_01.xml · nonDerivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,545 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 15:08 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionOption (right to buy) · Derivative | 6,603 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0001593968-18-000383 · primary_01.xml · derivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,397 Underlying: Common Stock · 6,603 shares Expires 2024-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options vest quarterly over four years commencing on the grant date. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 15:08 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionOption (right to buy) · Derivative | 27,500 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001593968-18-000383 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,500 Underlying: Common Stock · 27,500 shares Expires 2025-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options vest quarterly over four years commencing on the grant date. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 15:08 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 6,603 | $3.57 | $23,572.71 |
DisclosureSEC source: 0001593968-18-000383 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 15:08 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 27,500 | $3.02 | $83,050.00 |
DisclosureSEC source: 0001593968-18-000383 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 16:09 UTC | Vericel Corp VCEL · Entity 4481 | GrantOption (right to buy) · Derivative | 300,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001593968-18-000320 · primary_01.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-02-07 F1 · derivative.exercise_date: These options shall begin vesting on February 7, 2018 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| September 30, 2017 Filed Feb 13, 2018 17:15 UTC | Vericel Corp VCEL · Entity 4481 | GrantCommon Stock | 1,661 | $2.81 | $4,659.11 |
DisclosureSEC source: 0001104659-18-008852 · a5.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,304 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 30, 2017 Filed Feb 13, 2018 17:15 UTC | Vericel Corp VCEL · Entity 4481 | GrantCommon Stock | 3,771 | $2.38 | $8,974.98 |
DisclosureSEC source: 0001104659-18-008852 · a5.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,643 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 22, 2017 Filed May 24, 2017 17:59 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001593968-17-000711 · primary_01.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: VCEL · 90,000 shares Expires 2027-05-22 F1 · derivative.exercise_date: These options shall begin vesting on February 8, 2017 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| March 31, 2017 Filed Feb 13, 2018 17:15 UTC | Vericel Corp VCEL · Entity 4481 | GrantCommon Stock | 2,986 | $2.38 | $7,106.68 |
DisclosureSEC source: 0001104659-18-008852 · a5.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,872 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:25 UTC | Vericel Corp VCEL · Entity 4481 | GrantOption (right to buy) · Derivative | 167,825 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001593968-17-000252 · primary_01.xml · derivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,825 Underlying: VCEL · 167,825 shares Expires 2027-02-08 F1 · derivative.exercise_date: These options vest quarterly over four years commencing on the grant date. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:25 UTC | Vericel Corp VCEL · Entity 4481 | GrantOption (right to buy) · Derivative | 42,175 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001593968-17-000252 · primary_01.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,175 Underlying: VCEL · 42,175 shares Expires 2027-02-08 F1 · derivative.exercise_date: These options vest quarterly over four years commencing on the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.